ATE156365T1 - Osteogenische wachstumsfaktoren zur abgabe an zielorgan - Google Patents
Osteogenische wachstumsfaktoren zur abgabe an zielorganInfo
- Publication number
- ATE156365T1 ATE156365T1 AT92304142T AT92304142T ATE156365T1 AT E156365 T1 ATE156365 T1 AT E156365T1 AT 92304142 T AT92304142 T AT 92304142T AT 92304142 T AT92304142 T AT 92304142T AT E156365 T1 ATE156365 T1 AT E156365T1
- Authority
- AT
- Austria
- Prior art keywords
- growth factors
- delivery
- target organ
- osteogenic growth
- osteogenic
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1841—Transforming growth factor [TGF]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/548—Phosphates or phosphonates, e.g. bone-seeking
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds
- A61K47/552—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds one of the codrug's components being an antibiotic
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/645—Polycationic or polyanionic oligopeptides, polypeptides or polyamino acids, e.g. polylysine, polyarginine, polyglutamic acid or peptide TAT
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US69846791A | 1991-05-10 | 1991-05-10 |
Publications (1)
Publication Number | Publication Date |
---|---|
ATE156365T1 true ATE156365T1 (de) | 1997-08-15 |
Family
ID=24805377
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AT92304142T ATE156365T1 (de) | 1991-05-10 | 1992-05-08 | Osteogenische wachstumsfaktoren zur abgabe an zielorgan |
Country Status (8)
Country | Link |
---|---|
EP (1) | EP0512844B1 (de) |
JP (1) | JPH07500315A (de) |
AT (1) | ATE156365T1 (de) |
AU (1) | AU662155B2 (de) |
CA (1) | CA2102808A1 (de) |
DE (1) | DE69221368T2 (de) |
ES (1) | ES2104827T3 (de) |
WO (1) | WO1992020371A1 (de) |
Families Citing this family (62)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5766897A (en) * | 1990-06-21 | 1998-06-16 | Incyte Pharmaceuticals, Inc. | Cysteine-pegylated proteins |
US7056882B2 (en) | 1991-03-11 | 2006-06-06 | Curis, Inc. | Treatment to prevent loss of and/or increase bone mass in metabolic bone diseases |
US5674844A (en) * | 1991-03-11 | 1997-10-07 | Creative Biomolecules, Inc. | Treatment to prevent loss of and/or increase bone mass in metabolic bone diseases |
JP4235689B2 (ja) * | 1991-08-30 | 2009-03-11 | ストライカー・コーポレーション | 骨疾患を処置するための骨形成タンパク質 |
ATE238417T1 (de) | 1991-11-04 | 2003-05-15 | Inst Genetics Llc | Rekombinante knochenmorphogenetische protein heterodimere, zusammensetzungen und verfahren zur verwendung |
IL106159A0 (en) * | 1992-06-30 | 1993-10-20 | Dow Chemical Co | Targeted delivery of growth factors for bone regeneration |
KR100227406B1 (ko) | 1993-05-12 | 1999-12-01 | 브루스 엠. 에이센 | Bmp-11 조성물 |
DE4420157B4 (de) * | 1993-08-10 | 2013-04-25 | Biopharm Gesellschaft Zur Biotechnologischen Entwicklung Von Pharmaka Mbh | Neuer Wachstums/Differenzierungsfaktor der TGF-β-Familie |
JP3871713B2 (ja) | 1995-05-10 | 2007-01-24 | 協和醗酵工業株式会社 | 新規毒素複合体 |
US6902584B2 (en) | 1995-10-16 | 2005-06-07 | Depuy Spine, Inc. | Bone grafting matrix |
US5776193A (en) | 1995-10-16 | 1998-07-07 | Orquest, Inc. | Bone grafting matrix |
JPH09143093A (ja) * | 1995-11-17 | 1997-06-03 | Hoechst Japan Ltd | 軟骨・骨誘導性修復用材料 |
EP1364655B1 (de) | 1996-03-22 | 2010-12-29 | Stryker Corporation | Verfahren zur verbesserten funktionellen Erholung der motorischen Koordiination, der Sprache oder der Sinneswahrnehmung nach Trauma oder Ischämie des ZNS |
US6492508B1 (en) | 1996-06-03 | 2002-12-10 | United States Surgical Corp. A Division Of Tyco Healthcare Group | Nucleic acids encoding extracellular matrix proteins |
CA2279590A1 (en) | 1997-02-13 | 1998-08-20 | Bone Care International, Inc. | Targeted therapeutic delivery of vitamin d compounds |
WO1998035703A2 (en) * | 1997-02-14 | 1998-08-20 | The Salk Institute For Biological Studies | Methods and compositions for delivery of therapeutic agents to bone tissue employing conjugates of negatively charged peptide oligomers with therapeutic agents |
US7033765B1 (en) | 1997-02-20 | 2006-04-25 | Toronto Research Chemicals, Inc. | Site-specific drug delivery |
ATE296115T1 (de) * | 1997-02-20 | 2005-06-15 | David S Dime | Ortsspezifische arzneimittel verabreichung |
US8586781B2 (en) | 1998-04-02 | 2013-11-19 | Mbc Pharma, Inc. | Bone targeted therapeutics and methods of making and using the same |
US6663870B2 (en) * | 1998-12-07 | 2003-12-16 | Zymogenetics, Inc. | Methods for promoting growth of bone using zvegf3 |
US6458763B1 (en) * | 1999-09-17 | 2002-10-01 | Depuy Orthopeadics | Bone sialoprotein-based compositions for enhancing connective tissue repair |
AU2001286613A1 (en) | 2000-08-21 | 2002-03-04 | Rice University | Tissue engineering scaffolds promoting matrix protein production |
US7829074B2 (en) | 2001-10-18 | 2010-11-09 | Nektar Therapeutics | Hydroxypatite-targeting poly(ethylene glycol) and related polymers |
US6436386B1 (en) | 2000-11-14 | 2002-08-20 | Shearwater Corporation | Hydroxyapatite-targeting poly (ethylene glycol) and related polymers |
TWI329129B (en) | 2001-02-08 | 2010-08-21 | Wyeth Corp | Modified and stabilized gdf propeptides and uses thereof |
EP2260852A3 (de) * | 2001-04-10 | 2011-01-12 | MBC Pharma, Inc. | Konjugate aus Bisphosphonaten und Methoden zu deren Herstellung und Anwendung |
JP2006517995A (ja) * | 2003-02-19 | 2006-08-03 | ファルマシア・コーポレーション | 活性化されたポリエチレングリコールエステル類 |
EP1620079A1 (de) * | 2003-04-03 | 2006-02-01 | Semafore Pharmaceuticals, Inc. | Knochen-targeting von biologisch abbaubaren arzneimittelhaltigen nanoteilchen |
ES2282904T3 (es) | 2003-09-12 | 2007-10-16 | Wyeth | Barras solidas de fosfato calcico inyectables para el suministro de proteinas osteogenicas. |
HUE055861T2 (hu) | 2004-04-21 | 2021-12-28 | Alexion Pharma Inc | Csontbejuttató konjugátumok és azok alkalmazási módszere fehérjék csonthoz kötéséhez |
US20070081984A1 (en) | 2005-10-11 | 2007-04-12 | Shunji Tomatsu | Compositions and methods for treating hypophosphatasia |
TWI299257B (en) | 2005-05-16 | 2008-08-01 | Tung Hai Biotechnology Corp | γ-POLYGLUTAMIC ACID (γ-PGA, H FORM), γ-POLYGLUTAMATES AND γ-POLYGLUTAMATE HYDROGEL FOR USE AS NUTRITION SUPPLEMENTS IN DIETARY PRODUCTS |
WO2006130745A1 (en) * | 2005-06-01 | 2006-12-07 | Alza Corporation | Macromolecular conjugates of bone morphogenetic protein-7 |
EP2046391A4 (de) * | 2006-08-02 | 2013-03-20 | Univ Nebraska | Wirkstoffträger, ihre synthese und verfahren zu ihrer anwendung |
US8273325B2 (en) * | 2006-12-20 | 2012-09-25 | Ge Healthcare As | Contrast agents |
MX2010004400A (es) * | 2007-10-23 | 2010-05-20 | Nektar Therapeutics | Polimeros de multiples brazos dirigidos a la hidroxiapatita y conjugados de estos. |
WO2009075258A1 (ja) * | 2007-12-10 | 2009-06-18 | Cosmed Pharmaceutical Co., Ltd. | 経皮吸収製剤 |
WO2011045668A1 (en) | 2009-10-14 | 2011-04-21 | The Governors Of The University Of Alberta | Compounds having peptides conjugated to bone targeting moieties and methods of making and using thereof |
CN103153344A (zh) | 2010-04-30 | 2013-06-12 | 阿莱克森国际制药有限公司 | 用于治疗基质矿化障碍的方法、组合物、和试剂盒 |
WO2012088608A1 (en) | 2010-12-27 | 2012-07-05 | Enobia Canada Limited Partnership | Compositions comprising natriuretic peptides and methods of use thereof |
WO2013019874A1 (en) | 2011-08-01 | 2013-02-07 | Mbc Pharma, Inc. | Vitamin b6 derivatives of nucleotides, acyclonucleotides and acyclonucleoside phosphonates |
WO2013119956A1 (en) | 2012-02-09 | 2013-08-15 | Life Technologies Corporation | Conjugated polymeric particle and method of making same |
US10052366B2 (en) | 2012-05-21 | 2018-08-21 | Alexion Pharmaceuticsl, Inc. | Compositions comprising alkaline phosphatase and/or natriuretic peptide and methods of use thereof |
CN106456723B (zh) * | 2014-04-29 | 2021-03-09 | 康达医药科技有限公司 | 采用精氨酸酶i调节免疫系统的方法和组合物 |
WO2016007873A1 (en) | 2014-07-11 | 2016-01-14 | The Regents Of The University Of Michigan | Compositions and methods for treating craniosynostosis |
CN107405390A (zh) | 2014-12-05 | 2017-11-28 | 阿雷克森制药公司 | 用重组碱性磷酸酶治疗癫痫 |
CA2973883A1 (en) | 2015-01-28 | 2016-08-04 | Alexion Pharmaceuticals, Inc. | Methods of treating a subject with an alkaline phosphatase deficiency |
US10279044B2 (en) | 2015-05-29 | 2019-05-07 | Purdue Research Foundation | Bone fracture repair by targeting of agents that promote bone healing |
CN107922974B (zh) | 2015-07-02 | 2021-11-09 | 生命技术公司 | 羧基官能亲水微珠的偶合 |
US10150992B2 (en) | 2015-07-06 | 2018-12-11 | Life Technologies Corporation | Substrates and methods useful in sequencing |
EP3337894A1 (de) | 2015-08-17 | 2018-06-27 | Alexion Pharmaceuticals, Inc. | Herstellung von alkalischen phosphatasen |
US11229686B2 (en) | 2015-09-28 | 2022-01-25 | Alexion Pharmaceuticals, Inc. | Reduced frequency dosage regimens for tissue non-specific alkaline phosphatase (TNSALP)-enzyme replacement therapy of hypophosphatasia |
US11400140B2 (en) | 2015-10-30 | 2022-08-02 | Alexion Pharmaceuticals, Inc. | Methods for treating craniosynostosis in a patient |
WO2017155569A1 (en) | 2016-03-08 | 2017-09-14 | Alexion Pharmaceuticals, Inc. | Methods for treating hypophosphatasia in children |
WO2017160855A1 (en) | 2016-03-15 | 2017-09-21 | The Regents Of The University Of California | Bone-targeting therapeutic conjugate and methods of making and using the same |
WO2017173413A1 (en) | 2016-04-01 | 2017-10-05 | Alexion Pharmaceuticals, Inc. | Treating muscle weakness with alkaline phosphatases |
WO2017173395A1 (en) | 2016-04-01 | 2017-10-05 | Alexion Pharmaceuticals, Inc. | Methods for treating hypophosphatasia in adolescents and adults |
EP3464573A4 (de) | 2016-06-06 | 2020-02-19 | Alexion Pharmaceuticals, Inc. | Auswirkungen von metallen auf die herstellung von alkalischen phosphatasen |
JP7018933B2 (ja) | 2016-08-18 | 2022-02-14 | アレクシオン ファーマシューティカルズ, インコーポレイテッド | 気管気管支軟化症の治療方法 |
CN110719786A (zh) | 2017-03-31 | 2020-01-21 | 阿雷克森制药公司 | 用于治疗成人和青少年的低磷酸酯酶症(hpp)的方法 |
JP2021519590A (ja) | 2018-03-30 | 2021-08-12 | アレクシオン ファーマシューティカルズ, インコーポレイテッド | 糖タンパク質の製造 |
WO2019232280A1 (en) * | 2018-05-30 | 2019-12-05 | Purdue Research Foundation | Targeting anabolic drugs for accelerated fracture repair |
Family Cites Families (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4179337A (en) | 1973-07-20 | 1979-12-18 | Davis Frank F | Non-immunogenic polypeptides |
GB1578348A (en) | 1976-08-17 | 1980-11-05 | Pharmacia Ab | Products and a method for the therapeutic suppression of reaginic antibodies responsible for common allergic |
JPS6023084B2 (ja) | 1979-07-11 | 1985-06-05 | 味の素株式会社 | 代用血液 |
US4455256A (en) | 1981-05-05 | 1984-06-19 | The Regents Of The University Of California | Bone morphogenetic protein |
US4294753A (en) | 1980-08-04 | 1981-10-13 | The Regents Of The University Of California | Bone morphogenetic protein process |
DE3380726D1 (en) | 1982-06-24 | 1989-11-23 | Japan Chem Res | Long-acting composition |
US4434094A (en) | 1983-04-12 | 1984-02-28 | Collagen Corporation | Partially purified osteogenic factor and process for preparing same from demineralized bone |
US4863899A (en) * | 1983-05-09 | 1989-09-05 | Todaro George J | Biologically active polypeptides |
US4795804A (en) | 1983-08-16 | 1989-01-03 | The Regents Of The University Of California | Bone morphogenetic agents |
DE3588058T3 (de) | 1984-07-16 | 2005-04-07 | Celtrix Pharmaceuticals, Inc., Palo Alto | Knorpel-induzierende Polypeptid-Faktoren aus Knochen |
US4830847A (en) | 1985-06-28 | 1989-05-16 | The Procter & Gamble Company | Diphosphonate-derivatized macromolecules |
US4806523A (en) | 1985-08-06 | 1989-02-21 | Collagen Corporation | Method of treating inflammation |
IL83003A (en) | 1986-07-01 | 1995-07-31 | Genetics Inst | Factors that soak bone formation |
IN165717B (de) * | 1986-08-07 | 1989-12-23 | Battelle Memorial Institute | |
DE68929472T2 (de) | 1988-04-08 | 2004-05-13 | Stryker Corp., Kalamazoo | Biosynthetische knochenbildende Proteine, und sie enthaltende knochenbildende Vorrichtungen |
US5162430A (en) | 1988-11-21 | 1992-11-10 | Collagen Corporation | Collagen-polymer conjugates |
US5118667A (en) * | 1991-05-03 | 1992-06-02 | Celtrix Pharmaceuticals, Inc. | Bone growth factors and inhibitors of bone resorption for promoting bone formation |
-
1992
- 1992-05-07 CA CA002102808A patent/CA2102808A1/en not_active Abandoned
- 1992-05-07 AU AU19947/92A patent/AU662155B2/en not_active Ceased
- 1992-05-07 WO PCT/US1992/003840 patent/WO1992020371A1/en active Application Filing
- 1992-05-07 JP JP5500099A patent/JPH07500315A/ja active Pending
- 1992-05-08 ES ES92304142T patent/ES2104827T3/es not_active Expired - Lifetime
- 1992-05-08 EP EP92304142A patent/EP0512844B1/de not_active Expired - Lifetime
- 1992-05-08 AT AT92304142T patent/ATE156365T1/de not_active IP Right Cessation
- 1992-05-08 DE DE69221368T patent/DE69221368T2/de not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
AU1994792A (en) | 1992-12-30 |
JPH07500315A (ja) | 1995-01-12 |
EP0512844B1 (de) | 1997-08-06 |
EP0512844A1 (de) | 1992-11-11 |
AU662155B2 (en) | 1995-08-24 |
ES2104827T3 (es) | 1997-10-16 |
DE69221368T2 (de) | 1997-12-18 |
CA2102808A1 (en) | 1992-11-11 |
DE69221368D1 (de) | 1997-09-11 |
WO1992020371A1 (en) | 1992-11-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ATE156365T1 (de) | Osteogenische wachstumsfaktoren zur abgabe an zielorgan | |
IL122473A (en) | Fgfr3 as a marker for mesenchymal skeletal progenitor cells | |
DE69528058T2 (de) | Bmp-9 zusammensetzungen | |
ATE393831T1 (de) | Zusammensetzung zur in vivo erzeugung von therapeutischen produkten | |
ATE273025T1 (de) | Dha-pharmazeutisches produkt konjugate | |
EP0627899A4 (de) | Injektierbare, keramische verbindungen sowie verfahren zur deren herstellung und anwendung. | |
CO4520232A1 (es) | Conjugados de interferon-polimero y proceso para preparar el mismo | |
PT1117440E (pt) | Composicoes farmaceuticas que contem paclitaxel | |
ATE196296T1 (de) | Dolastatin analog | |
KR100278905B1 (ko) | 연골또는뼈의결손또는병변을치료하고치유시키기위한방법및조성물 | |
DK2174674T3 (da) | Fremgangsmåder og sammensætninger til heling og reparation af led-brusk | |
DE69636989D1 (de) | Bioaktive lasttragende zusammensetzungen zum knochenverbund | |
ATE175441T1 (de) | Bmp-9 zusammensetzungen | |
DE69031939T2 (de) | Osteoinduktive zusammensetzungen | |
ATE237633T1 (de) | Analogen des keratinozytenwachstumfaktors | |
DK0637254T3 (da) | Biomaterialer til knogleerstatninger | |
ES2132399T3 (es) | Composicion estimulante del crecimiento de osteoblastos que contiene pdgf y vitamina d. | |
ATE104511T1 (de) | Abwehrmittel. | |
BR9611571A (pt) | Composição farmacêutica estável composição farmacêutica kit para administração de ngf e método de aumento da estabilidade de ngf | |
DE60017141D1 (de) | Replikationskompetente anti-tumor vektoren | |
FI923952A0 (fi) | Herbicida kompositioner. | |
NO20013744L (no) | Fremgangsmåter og blandinger for heling og reparasjon av leddbrusk | |
DK1165102T3 (da) | Matrixproteinpræparater til podning i ikke-mineraliseret væv | |
PT884293E (pt) | Composicoes fertilizantes a base de derivados naturais ou sinteticos de aminopurina ou de extractos de algas ricas nesses derivados em associacao com uma fonte de calcio | |
PT1108716E (pt) | Derivados de taxano em c7 e composicoes farmaceuticas que os contem |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |